Literature DB >> 1457349

A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.

L S Manning1, J D Berger, H L O'Donoghue, G N Sheridan, P G Claringbold, J H Turner.   

Abstract

The 5T33 multiple myeloma is one of a series of transplantable murine myelomas arising spontaneously in C57BL/KaLwRij mice. This study describes the establishment and characterisation of the 5T33 murine myeloma in vitro as a cultured cell line in terms of its morphology, growth rate, expression of paraprotein (IgG2b) and tumorigenicity in syngeneic animals. The 5T33 cell line has been in continuous culture for over 10 months and has achieved more than passage 34. In culture, 5T33 myeloma grows as single cells or in small clusters of loosely adherent cells on an adherent stromal cell layer. Maximum doubling time is approximately 25 h, and over 90% of the cells express cytoplasmic IgG2b paraprotein. The cultured 5T33 myeloma cells are highly tumorigenic in C57BL/KaLwRij mice with as few as 500 cells inducing paralysis and death as early as day 36 post-tumour inoculation. Kinetics of tumour development and detection of IgG2b paraprotein are dose dependent. Two weeks following intravenous inoculation of 5 x 10(5) cultured 5T33 myeloma cells, tumour cells were readily identified in the bone marrow. By 3 weeks post-tumour inoculation, 5T33 myeloma cells were found in various tissues throughout the animal. Studies are now underway to determine the sensitivity of this cell line to various therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457349      PMCID: PMC1978028          DOI: 10.1038/bjc.1992.415

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Toward a cure for multiple myeloma?

Authors:  B Barlogie
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

2.  Agarose gel electrophoresis.

Authors:  J O Jeppsson; C B Laurell; B Franzén
Journal:  Clin Chem       Date:  1979-04       Impact factor: 8.327

Review 3.  Treatment of refractory multiple myeloma and considerations for future therapy.

Authors:  R A Kyle; P R Greipp; M A Gertz
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

Review 4.  He's not going to talk about in vitro predictive assays again, is he?

Authors:  D D Von Hoff
Journal:  J Natl Cancer Inst       Date:  1990-01-17       Impact factor: 13.506

Review 5.  Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications.

Authors:  H Mellstedt; G Holm; M Björkholm
Journal:  Adv Cancer Res       Date:  1984       Impact factor: 6.242

6.  Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.

Authors:  M Hjorth; L Hellquist; E Holmberg; B Magnusson; S Rödjer; J Westin
Journal:  Br J Haematol       Date:  1990-02       Impact factor: 6.998

7.  Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease.

Authors:  J W Croese; M H Van den Enden-Vieveen; J Radl
Journal:  Neoplasma       Date:  1991       Impact factor: 2.575

8.  High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.

Authors:  B Barlogie; R Alexanian; K A Dicke; G Zagars; G Spitzer; S Jagannath; L Horwitz
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

9.  Chemotherapy for multiple myeloma.

Authors:  R Alexanian; R Dreicer
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

10.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

View more
  15 in total

1.  T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation.

Authors:  Sarah E Henrickson; Thorsten R Mempel; Irina B Mazo; Bai Liu; Maxim N Artyomov; Huan Zheng; Antonio Peixoto; Michael P Flynn; Balimkiz Senman; Tobias Junt; Hing C Wong; Arup K Chakraborty; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2008-01-20       Impact factor: 25.606

2.  Preclinical animal models of multiple myeloma.

Authors:  Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2016-02-03

3.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

4.  Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Authors:  Jo Caers; Dirk Hose; Ine Kuipers; Tomas Jan Bos; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Hartmut Goldschmidt; Ben Van Camp; Bernard Klein; Karin Vanderkerken
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

5.  Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.

Authors:  Tyce J Kearl; Weiqing Jing; Jill A Gershan; Bryon D Johnson
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

6.  Age matters:  Young T lymphocytes offer better protection from myeloma proliferation.

Authors:  Alexander F Glick; Yan S Song; Brian Hwang; John Lillvis; Pat Zanzonico; Camil Fuchs; Roger N Pearse; Paul Szabo; Marc E Weksler
Journal:  Immun Ageing       Date:  2013-02-18       Impact factor: 6.400

7.  VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.

Authors:  Francesca Fontana; Michael J Scott; John S Allen; Xiaoxia Yang; Grace Cui; Dipanjan Pan; Noriko Yanaba; Mark A Fiala; Julie O'Neal; Anne H Schmieder-Atteberry; Julie Ritchey; Michael Rettig; Kathleen Simons; Steven Fletcher; Ravi Vij; John F DiPersio; Gregory M Lanza
Journal:  Clin Cancer Res       Date:  2020-12-22       Impact factor: 13.801

8.  Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model.

Authors:  Mari I Suominen; Jenni Mäki-Jouppila; Anna Huhtinen; Birgitta Sjöholm; Jukka P Rissanen; Anniina Luostarinen; Katja M Fagerlund; Esa Alhoniemi; Gerhard Siemeister; Dominik Mumberg; Sanna-Maria Käkönen; Arne Scholz
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 9.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

10.  A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Authors:  Peter O Hofgaard; Henriette C Jodal; Kurt Bommert; Bertrand Huard; Jo Caers; Harald Carlsen; Rolf Schwarzer; Nicole Schünemann; Franziska Jundt; Mona M Lindeberg; Bjarne Bogen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.